Surmodics, Inc.

Equities

SRDX

US8688731004

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 03:23:55 2024-06-26 pm EDT			5-day change	1st Jan Change
41.94 ^USD	-0.04%		-0.01%	+15.39%

Jun. 10	Surmodics Signs Group Purchasing Deal With Premier	MT
Jun. 10	Surmodics, Inc. Receives Thrombectomy Products Agreement with Premier, Inc	CI

Tranche Update on Surmodics, Inc.'s Equity Buyback Plan announced on November 6, 2014.

May 01, 2024 at 08:16 am EDT

From January 1, 2024 to March 31, 2024, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 1,044,054 shares, representing 7.74% for $24.7 million under the buyback announced on November 6, 2014.

Latest news about Surmodics, Inc.

Surmodics Signs Group Purchasing Deal With Premier	Jun. 10	MT
Surmodics, Inc. Receives Thrombectomy Products Agreement with Premier, Inc	Jun. 10	CI
Barrington Research Downgrades SurModics to Market Perform From Outperform	May. 30	MT
Needham Downgrades SurModics to Hold From Buy	May. 29	MT
Sector Update: Health Care Stocks Lean Lower Premarket Wednesday	May. 29	MT
Rising Bond Yields Fueling Losses for US Equity Futures Pre-Bell	May. 29	MT
Sector Update: Health Care	May. 29	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday After Fed Speaker's Hawkish Comments	May. 29	MT
Top Premarket Gainers	May. 29	MT
SurModics Agrees to be Acquired by Private Equity Firm GTCR for $627 Million; Shares Rise Pre-Bell	May. 29	MT
GTCR LLC entered into a definitive agreement to acquire Surmodics, Inc. for approximately $620 million.	May. 28	CI
Barrington Ups Price Target on SurModics to $71 From $70, Maintains Outperform Rating	May. 02	MT
Top Midday Gainers	May. 01	MT
Tranche Update on Surmodics, Inc.'s Equity Buyback Plan announced on November 6, 2014.	May. 01	CI
Transcript : Surmodics, Inc., Q2 2024 Earnings Call, May 01, 2024	May. 01
Earnings Flash (SRDX) SURMODICS Reports Q2 Revenue $32M, vs. Street Est of $28.8M	May. 01	MT
Earnings Flash (SRDX) SURMODICS Reports Q2 EPS $0.07, vs. Street Est of $-0.32	May. 01	MT
Surmodics, Inc. Revises Earnings Guidance for the Fiscal Year 2024	May. 01	CI
Surmodics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	May. 01	CI
North American Morning Briefing : Traders Wait for -2-	May. 01	DJ
Barrington Trims Price Target on SurModics to $70 From $71, Keeps Outperform Rating	Feb. 06	MT
Needham Adjusts SurModics' Price Target to $47 From $44, Maintains Buy Rating	Feb. 01	MT
Tranche Update on Surmodics, Inc.'s Equity Buyback Plan announced on November 6, 2014.	Feb. 01	CI
Surmodics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 01	CI
Transcript : Surmodics, Inc., Q1 2024 Earnings Call, Feb 01, 2024	Feb. 01

Chart Surmodics, Inc.

Duration

Period

More charts

Company Profile

Surmodics, Inc. is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The Company's segments include Medical Device and IVD. The Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral, coronary and structural heart. It manufactures vascular intervention medical devices, including drug-coated balloons, and radial access balloon catheters and guide sheaths. The IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-07-30 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Surmodics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

41.96 USD

Average target price

43 USD

Spread / Average Target

+2.48%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
SURMODICS, INC.	+15.39%	598M
ABBOTT LABORATORIES	-4.72%	184B
MEDTRONIC PLC	-2.80%	103B
BECTON, DICKINSON AND COMPANY	-4.88%	67.59B
CENCORA, INC.	+15.63%	46.93B
DEXCOM, INC.	-8.49%	43.87B
HOYA CORPORATION	+8.28%	41.2B
METTLER-TOLEDO INTERNATIONAL, INC.	+17.05%	30.47B
TERUMO CORPORATION	+13.59%	24.16B
WEST PHARMACEUTICAL SERVICES, INC.	-7.50%	23.57B

Other Medical Equipment, Supplies & Distribution